COVID-19 and Diabetes: Persistent Cardiovascular and Renal Risks in the Post-Pandemic Landscape DOI Creative Commons
Tzu-Shan Huang,

Jo-Yen Chao,

Ho-Hsiang Chang

et al.

Life, Journal Year: 2025, Volume and Issue: 15(5), P. 726 - 726

Published: April 30, 2025

The Coronavirus Disease 2019 (COVID-19) pandemic, caused by Severe Acute Respiratory Syndrome 2 (SARS-CoV-2), disproportionately affects individuals with diabetes mellitus (DM) exacerbating cardiovascular and renal complications. This increased risk is mediated through immune dysfunction, chronic inflammation, hyperglycemia, dysregulation of renin-angiotensin system dysregulation, endothelial hypercoagulability. Epidemiological studies indicate a two-fold stroke end-stage disease in SARS-CoV-2-infected diabetes, along 60% higher disease. While antidiabetic therapies like sodium-glucose cotransporter-2 inhibitors glucagon-like peptide-1 receptor agonists show potential protective effects, insulin use hospitalized patients linked to mortality. Vaccination crucial reducing severe COVID-19 outcomes mitigating post-infection complications, including new-onset diabetes. concerns exist regarding vaccine-associated nephropathy thromboembolic events, these risks are thought be minimal compared the benefits. As shifts an endemic phase, long-term DM remain uncertain, highlighting urgent need for continued research targeted management strategies.

Language: Английский

Acute Tubulointerstitial Nephritis: Clinical Features, Immunological Insights, and Diagnostic and Treatment Approaches Update on acute tubulointerstitial nephritis DOI Creative Commons
Tuncay Şahutoğlu, Mark A. Perazella

Kidney International Reports, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Language: Английский

Citations

0
COVID-19 and Diabetes: Persistent Cardiovascular and Renal Risks in the Post-Pandemic Landscape DOI Creative Commons
Tzu-Shan Huang,

Jo-Yen Chao,

Ho-Hsiang Chang

et al.

Life, Journal Year: 2025, Volume and Issue: 15(5), P. 726 - 726

Published: April 30, 2025

The Coronavirus Disease 2019 (COVID-19) pandemic, caused by Severe Acute Respiratory Syndrome 2 (SARS-CoV-2), disproportionately affects individuals with diabetes mellitus (DM) exacerbating cardiovascular and renal complications. This increased risk is mediated through immune dysfunction, chronic inflammation, hyperglycemia, dysregulation of renin-angiotensin system dysregulation, endothelial hypercoagulability. Epidemiological studies indicate a two-fold stroke end-stage disease in SARS-CoV-2-infected diabetes, along 60% higher disease. While antidiabetic therapies like sodium-glucose cotransporter-2 inhibitors glucagon-like peptide-1 receptor agonists show potential protective effects, insulin use hospitalized patients linked to mortality. Vaccination crucial reducing severe COVID-19 outcomes mitigating post-infection complications, including new-onset diabetes. concerns exist regarding vaccine-associated nephropathy thromboembolic events, these risks are thought be minimal compared the benefits. As shifts an endemic phase, long-term DM remain uncertain, highlighting urgent need for continued research targeted management strategies.

Language: Английский

Citations

0